Protecting the intellectual property of new drugs is complicated but essential for pharmaceutical companies. Patents are important in this respect, but by themselves they do not always create a sufficiently favourable environment for encouraging drug development.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Patent, FDA, NME, Taiwanese Pharmaceutical Affairs Act, Hatch-Waxman Act, pharmaceuticals
